Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.
Zollinger DR, Rivers E, Fine A, Huang Y, Son J, Kalyan A, Gray W, Baharian G, Hammond C, Ram R, Ringman L, Hafez D, Savel D, Patel V, Dantone M, Guo C, Childress M, Xu C, Johng D, Wallden B, Pokharel P, Camara W, Hegde PS, Hughes J, Carter C, Davarpanah N, Degaonkar V, Gupta P, Mariathasan S, Powles T, Ferree S, Dennis L, Young A. Zollinger DR, et al. Among authors: powles t. PLoS One. 2024 May 16;19(5):e0302129. doi: 10.1371/journal.pone.0302129. eCollection 2024. PLoS One. 2024. PMID: 38753705 Free PMC article.
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Powles T, et al. ESMO Open. 2024 Apr 19;9(5):102994. doi: 10.1016/j.esmoop.2024.102994. Online ahead of print. ESMO Open. 2024. PMID: 38642472 Free PMC article.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: powles t. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Saad E, Gebrael G, Semaan K, Eid M, Saliby RM, Labaki C, Sayegh N, Wells JC, Takemura K, Ernst MS, Lemelin A, Basappa NS, Wood LA, Powles T, Ernst DS, Lalani AA, Agarwal N, Xie W, Heng DYC, Choueiri TK. Saad E, et al. Among authors: powles t. Oncologist. 2024 Apr 17:oyae072. doi: 10.1093/oncolo/oyae072. Online ahead of print. Oncologist. 2024. PMID: 38630540 Free article.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, Fontana E, Giannatempo P, Deville JL, Pouessel D, Yoon S, Powles T, Bernat M, Häckl M, Marszewska M, McKernan P, Saulay M, Scaleia F, Engelhardt M, Loriot Y, Siefker-Radtke A, De Santis M. Necchi A, et al. Among authors: powles t. JNCI Cancer Spectr. 2024 Apr 16:pkae030. doi: 10.1093/jncics/pkae030. Online ahead of print. JNCI Cancer Spectr. 2024. PMID: 38627238
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T. Young M, et al. Among authors: powles t. Clin Genitourin Cancer. 2024 Mar 8;22(3):102072. doi: 10.1016/j.clgc.2024.102072. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38615487 Free article.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Motzer RJ, et al. Among authors: powles t. Eur Urol. 2024 Apr 5:S0302-2838(24)02234-6. doi: 10.1016/j.eururo.2024.03.015. Online ahead of print. Eur Urol. 2024. PMID: 38582713 Free article.
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer RJ, Powles T, Rini BI, Albiges L, Pal SK, McGregor BA, McKay RR, Signoretti S, Van Allen EM, Shukla SA, Choueiri TK, Braun DA. Saliby RM, et al. Among authors: powles t. Cancer Cell. 2024 May 13;42(5):732-735. doi: 10.1016/j.ccell.2024.03.002. Epub 2024 Apr 4. Cancer Cell. 2024. PMID: 38579722
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Grünwald V, et al. Among authors: powles t. Front Oncol. 2024 Mar 1;13:1343027. doi: 10.3389/fonc.2023.1343027. eCollection 2023. Front Oncol. 2024. PMID: 38495081 Free PMC article.
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Powles T, et al. Ann Oncol. 2024 Mar 13:S0923-7534(24)00075-9. doi: 10.1016/j.annonc.2024.03.001. Online ahead of print. Ann Oncol. 2024. PMID: 38490358 No abstract available.
809 results